2hz4
|
Abl kinase domain unligated and in complex with tetrahydrostaurosporine
OverviewOverview
Chronic myelogenous leukaemia (CML) results from the Bcr-Abl oncoprotein, which has a constitutively activated Abl tyrosine kinase domain. Although, most chronic phase CML patients treated with imatinib as first-line, therapy maintain excellent durable responses, patients who have progressed, to advanced-stage CML frequently fail to respond or lose their response to, therapy owing to the emergence of drug-resistant mutants of the protein., More than 40 such point mutations have been observed in imatinib-resistant, patients. The crystal structures of wild-type and mutant Abl kinase in, complex with imatinib and other small-molecule Abl inhibitors were, determined, with the aim of understanding the molecular basis of, resistance and to aid in the design and optimization of inhibitors active, against the resistance mutants. These results are presented in a way which, illustrates the approaches used to generate multiple structures, the type, of information that can be gained and the way that this information is, used to support drug discovery.
DiseaseDisease
Known diseases associated with this structure: Leukemia, Philadelphia chromosome-positive, resistant to imatinib OMIM:[189980]
About this StructureAbout this Structure
2HZ4 is a Single protein structure of sequence from Homo sapiens with 4ST as ligand. Active as Non-specific protein-tyrosine kinase, with EC number 2.7.10.2 Full crystallographic information is available from OCA.
ReferenceReference
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia., Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW, Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):80-93. Epub 2006, Dec 13. PMID:17164530
Page seeded by OCA on Mon Nov 12 22:38:48 2007